Konecranes ABP (0MET)
London Stock Exchange · UK · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 27.24 |
|---|---|
| 52-week range | 24.60 – 35.30 |
| Return, 1 month / 3 months | −14.3% / +3.0% |
| Return, 1 year / 3 years | +3.1% / +216.8% |
| Trend | Below its 200-day average |
| RSI (14) | 37 |
| Volatility (1 year) | 38.9% |
| Worst drawdown (1 year) | -19.3% |
| Average daily value traded | 1.59M EUR |
| Dividend yield | 24.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Konecranes is a Finnish engineering group based in Hyvinkää that builds and services lifting equipment. It makes overhead cranes, hoists and other material-handling machinery for factories and industrial sites, and supplies container-handling equipment and automation systems for ports and terminals. The company also runs a large service business, maintaining and modernising lifting equipment for customers across manufacturing, process industries and port operations around the world.
The shares are listed on the London Stock Exchange in UK under the code 0MET, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Konecranes ABP (0MET) trades on the London Stock Exchange in UK. It last closed at EUR 27.24 on 27 October 2026.
Its price-based Market X-Ray is 56 out of 100 (a fair price profile), ranking 1,632 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 3.1% and over the last three months it rose 3.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -5.0% | ||
| From 52-week high | -15.7% | ||
| Momentum | 54 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 3.0% | ||
| 6-month return | -11.7% | ||
| 12-month return, skipping the last month | 20.3% | ||
| Stability (higher is calmer) | 59 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 38.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.3% | ||
| Liquidity | 58 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.59M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 70 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 24.8% | ||
| Years with dividends | 5 |
Strengths
- Income: Dividend is high and has been paid regularly.
Weak spots
- Trend: Below its long-term averages and far from its highs.
Returns
| 1 week | −7.5% |
|---|---|
| 1 month | −14.3% |
| 3 months | +3.0% |
| 6 months | −11.7% |
| 1 year | +3.1% |
| 3 years | +216.8% |
| 5 years | +169.5% |
Signals
| 50-day / 200-day average | 29.58 / 28.66 |
|---|---|
| Golden / death cross (60 days) | Golden, 21 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.53 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 27 Mar 2026 | EUR 6.7500 |
| 28 Mar 2025 | EUR 1.6500 |
| 28 Mar 2024 | EUR 1.3500 |
| 30 Mar 2023 | EUR 1.2500 |
| 16 Jun 2022 | EUR 1.2500 |
| 31 Mar 2022 | EUR 0.0264 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.